Farhad Ravandi, MD, obtained his medical degree from St. Mary’s Hospital Medical School/Imperial College, University of London, London, UK, in 1988. Dr Ravandi completed his clinical residency in internal medicine at the University of Texas, Houston, TX, and later completed his clinical residency in hematology at the Baylor College of Medicine, Houston, TX. He then undertook his clinical fellowship in hematology/oncology at the University of Texas MD Anderson Cancer Center, Houston, TX, where he stayed to complete a fellowship in blood and marrow transplantation, hematology and stem cell transplantation in 2000.
Dr Ravandi has been a member of the UT MD Anderson Clinical Research Committee II since 2005 and is the Janiece and Stephen A. Lasher, Endowed Professor in the Department of Leukemia, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, Houston, TX. He is also currently Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas MD Anderson Cancer Center.
Speaking on novel acute leukemia therapeutics
Dr Ravandi’s research primarily focuses on the clinical impact of genetic mutations underlying the development and progression of acute leukemias, particularly acute myeloid leukemia (AML). He has several publications on the clinical impact of mutations such as PTPN11 and FLT3.
Dr Ravandi is also actively involved in several clinical trials looking into the treatment of AML particularly in patients bearing mutations. Dr Ravandi is the Principal Investigator for a Phase II trial (NCT04746235) investigating venetoclax and the combination of decitabine and cedazuridine for relapsed/refractory and newly diagnosed AML.